Application of aptamer-functionalized nanomaterials in molecular imaging of tumors
Source abstract
Abstract
Abstract Cancer is one of the most important causes of human death. Early diagnosis and treatment can make patients live longer. Therefore, there is an urgent need to develop early and accurate diagnosis method for tumors. Molecular imaging technology can be used for qualitative and quantitative analyses at cellular and molecular levels, which provides a new technology for accurate diagnosis of tumors. In recent years, various nanomaterials with unique properties have been used for tumor molecular imaging. Meanwhile, aptamers are becoming an indispensable element in the design of functional nanomaterials because of their small size, high stability, and convenient modification, especially giving nanomaterials the ability to recognize specific targets. Therefore, aptamer-functionalized nanomaterials (AFNs) provide unprecedented opportunities for the field of tumor diagnosis. Here we focus on the latest development of AFNs in the molecular imaging of tumors. First, we introduce the characteristics and advantages of common aptamer-modified organic nanomaterials and inorganic nanomaterials. Then, the applications of AFNs in fluorescence imaging, computed tomography, magnetic resonance imaging, radionuclide imaging, ultrasound imaging, photoacoustic imaging, and multimode fusion imaging are discussed. Finally, we provide some perspectives on the challenges and opportunities that have arisen from this promising area.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology, First Affiliated Hospital of Anhui Medical University , Hefei , 230022 , China
Jincheng People’s Hospital , Jincheng 048000 , China
Clinical Medical College of Hebei University , Baoding 071000 , China
Hebei University Affiliated Hospital , Baoding 071000 , China
References (100+)
Show source-provided references
1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Global Health. 2020;8:e180–90. 10.1016/S2214-109X(19)30488-7.10.1016/S2214-109X(19)30488-7 ↗
2. Whitaker K. Earlier diagnosis: The importance of cancer symptoms. Lancet Oncol. 2020;21:6–8. 10.1016/S1470-2045(19)30658-8.10.1016/S1470-2045(19)30658-8 ↗
3. Sa P, Sahoo SK. 15 - Recent advances in aptamer-based nanomaterials in imaging and diagnostics of cancer. In: Kesharwani P, editor. Aptamers engineered nanocarriers for cancer therapy. Sawston Cambridge: Woodhead Publishing; 2023. p. 347–66.10.1016/B978-0-323-85881-6.00007-5 ↗
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71:209–49. 10.3322/caac.21660.10.3322/caac.21660 ↗
5. Deng G, Zha H, Luo H, Zhou Y. Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer. Front Bioeng Biotechnol. 2023;11:1118546. 10.3389/fbioe.2023.1118546.10.3389/fbioe.2023.1118546 ↗
6. McGown LB, Joseph MJ, Pitner JB, Vonk GP, Linn CP. The nucleic acid ligand. A new tool for molecular recognition. Anal Chem. 1995;67:663–8A. 10.1021/ac00117a002.10.1021/ac00117a002 ↗
7. Zhou J, Rossi J. Aptamers as targeted therapeutics: Current potential and challenges. Nat Rev Drug Discov. 2017;16:440. 10.1038/nrd.2017.86.10.1038/nrd.2017.86 ↗
8. Guo W, Zhang C, Ma T, Liu X, Chen Z, Li S, et al. Advances in aptamer screening and aptasensors’ detection of heavy metal ions. J Nanobiotechnol. 2021;19:166. 10.1186/s12951-021-00914-4.10.1186/s12951-021-00914-4 ↗
9. di Leandro L, Giansanti F, Mei S, Ponziani S, Colasante M, Ardini M, et al. Aptamer-driven toxin gene delivery in U87 model glioblastoma cells. Front Pharmacol. 2021;12:588306. 10.3389/fphar.2021.588306.10.3389/fphar.2021.588306 ↗
10. Song W, Song Y, Li Q, Fan C, Lan X, Jiang D. Advances in aptamer-based nuclear imaging. Eur J Nucl Med Mol Imaging. 2022;49:2544–59. 10.1007/s00259-022-05782-0.10.1007/s00259-022-05782-0 ↗
11. Srivastava S, Abraham PR, Mukhopadhyay S. Aptamers: An emerging tool for diagnosis and therapeutics in tuberculosis. Front Cell Infect Microbiol. 2021;11:656421. 10.3389/fcimb.2021.656421.10.3389/fcimb.2021.656421 ↗
12. Liu X, Wang T, Wu Y, Tan Y, Jiang T, Li K, et al. Aptamer based probes for living cell intracellular molecules detection. Biosens Bioelectron. 2022;208:114231. 10.1016/j.bios.2022.114231.10.1016/j.bios.2022.114231 ↗
13. Pang X, Cui C, Wan S, Jiang Y, Zhang L, Xia L, et al. Bioapplications of cell-SELEX-generated aptamers in cancer diagnostics, therapeutics, theranostics, and biomarker discovery: A comprehensive review. Cancers. 2018;10:47. 10.3390/cancers10020047.10.3390/cancers10020047 ↗
14. He F, Wen N, Xiao D, Yan J, Xiong H, Cai S, et al. Aptamer-based targeted drug delivery systems: Current potential and challenges. Curr Med Chem. 2020;27:2189–219. 10.2174/0929867325666181008142831.10.2174/0929867325666181008142831 ↗
15. Ni S, Zhuo Z, Pan Y, Yu Y, Li F, Liu J, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces. 2021;13:9500–19. 10.1021/acsami.0c05750.10.1021/acsami.0c05750 ↗
16. Jin JO, Kim G, Hwang J, Han KH, Kwak M, Lee P. Nucleic acid nanotechnology for cancer treatment. Biochim Biophys Acta Rev Cancer. 2020;1874:188377. 10.1016/j.bbcan.2020.188377.10.1016/j.bbcan.2020.188377 ↗
17. Rastogi A, Yadav K, Mishra A, Singh MS, Chaudhary S, Manohar R, et al. Early diagnosis of lung cancer using magnetic nanoparticles-integrated systems. Nanotechnol Rev. 2022;11:544–74. 10.1515/ntrev-2022-0032.10.1515/ntrev-2022-0032 ↗
18. Mohapatra D, Pratap R, Pandey V, Shreya S, Naik GG, Mandal SC, et al. Bioengineered dual fluorescent carbon nano dots from Indian long pepper leaves for multifaceted environmental and health utilities. Env Sci Pollut Res. 2023;30:52182–208. 10.1007/s11356-023-25887-9.10.1007/s11356-023-25887-9 ↗
19. Naik K, Chaudhary S, Ye L, Parmar AS. A strategic review on carbon quantum dots for cancer-diagnostics and treatment. Front Bioeng Biotechnol. 2022;10:882100. 10.3389/fbioe.2022.882100.10.3389/fbioe.2022.882100 ↗
20. Ali N, Zaman A, Sajid M, Bég O, Dr. Shamshuddin MD, Kadir A. Numerical simulation of time-dependent non-Newtonian nano-pharmacodynamic transport phenomena in a tapered overlapping stenosed artery. Nanosci Technol. 2018;9:247–82. 10.1615/NanoSciTechnolIntJ.2018027297.10.1615/NanoSciTechnolIntJ.2018027297 ↗
21. Ma X, Li SJ, Liu Y, Zhang T, Xue P, Kang Y, et al. Bioengineered nanogels for cancer immunotherapy. Chem Soc Rev. 2022;51:5136–74. 10.1039/d2cs00247g.10.1039/D2CS00247G ↗
22. Li X, Li W, Wang M, Liao Z. Magnetic nanoparticles for cancer theranostics: Advances and prospects. J Control Rel. 2021;335:437–48. 10.1016/j.jconrel.2021.05.042.10.1016/j.jconrel.2021.05.042 ↗
23. Waris A, Ali A, Khan AU, Asim M, Zamel D, Fatima K, et al. Applications of various types of nanomaterials for the treatment of neurological disorders. Nanomaterials. 2022;12:2140. 10.3390/nano12132140.10.3390/nano12132140 ↗
24. Purushothaman B, Song JM. Ag2S quantum dot theragnostics. Biomater Sci. 2021;9:51–69. 10.1039/d0bm01576h.10.1039/D0BM01576H ↗
25. Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: Current progress and perspectives. J Hematol Oncol. 2021;14:85. 10.1186/s13045-021-01096-0.10.1186/s13045-021-01096-0 ↗
26. Sharifi J, Khirehgesh MR, Safari F, Akbari B. EGFR and anti-EGFR nanobodies: Review and update. J Drug Target. 2021;29:387–402. 10.1080/1061186X.2020.1853756.10.1080/1061186X.2020.1853756 ↗
27. Sargazi S, Er S, Mobashar A, Gelen SS, Rahdar A, Ebrahimi N, et al. Aptamer-conjugated carbon-based nanomaterials for cancer and bacteria theranostics: A review. Chem-Biol Interact. 2022;361:109964. 10.1016/j.cbi.2022.109964.10.1016/j.cbi.2022.109964 ↗
28. Li D, Zhao J, Ma J, Yang H, Zhang X, Cao Y, et al. GMT8 aptamer conjugated PEGylated Ag@Au core-shell nanoparticles as a novel radiosensitizer for targeted radiotherapy of glioma. Colloid Surf B-Biointerfaces. 2022;211:112330. 10.1016/j.colsurfb.2022.112330.10.1016/j.colsurfb.2022.112330 ↗
29. Yang J, Qu J, Teng X, Zhu W, Xu Y, Yang Y, et al. Tumor microenvironment-responsive hydrogel for direct extracellular ATP imaging-guided surgical resection with clear boundaries. Adv Healthc Mater. 2023;e2301084. 10.1002/adhm.202301084.10.1002/adhm.202301084 ↗
30. Li M, Yang G, Zheng Y, Lv J, Zhou W, Zhang H, et al. NIR/pH-triggered aptamer-functionalized DNA origami nanovehicle for imaging-guided chemo-phototherapy. J Nanobiotechnol. 2023;21:186. 10.1186/s12951-023-01953-9.10.1186/s12951-023-01953-9 ↗
31. Abraham T, McGovern CO, Linton SS, Wilczynski Z, Adair JH, Matters GL. Aptamer-targeted calcium phosphosilicate nanoparticles for effective imaging of pancreatic and prostate cancer. Int J Nanomed. 2021;16:2297–309. 10.2147/IJN.S295740.10.2147/IJN.S295740 ↗
32. Agnello L, Tortorella S, D’Argenio A, Carbone C, Camorani S, Locatelli E, et al. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. J Exp Clin Cancer Res. 2021;40:239. 10.1186/s13046-021-02039-w.10.1186/s13046-021-02039-w ↗
33. Zhao J, Liu P, Ma J, Li D, Yang H, Chen W, et al. Enhancement of radiosensitization by silver nanoparticles functionalized with polyethylene glycol and aptamer As1411 for glioma irradiation therapy. Int J Nanomed. 2019;14:9483–96. 10.2147/IJN.S224160.10.2147/IJN.S224160 ↗
34. Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics. 2019;9:837–52. 10.7150/thno.30228.10.7150/thno.30228 ↗
35. Kang SJ, Jeong HY, Kim MW, Jeong IH, Choi MJ, You YM, et al. Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis. Nanoscale. 2018;10:19338–50. 10.1039/c8nr05099f.10.1039/C8NR05099F ↗
36. Jia R, He X, Ma W, Lei Y, Cheng H, Sun H, et al. Aptamer-functionalized activatable DNA tetrahedron nanoprobe for PIWI-interacting RNA imaging and regulating in cancer cells. Anal Chem. 2019;91:15107–13. 10.1021/acs.analchem.9b03819.10.1021/acs.analchem.9b03819 ↗
37. Zhang Y, Guo S, Huang H, Mao G, Ji X, He Z. Silicon nanodot-based aptasensor for fluorescence turn-on detection of mucin 1 and targeted cancer cell imaging. Anal Chim Acta. 2018;1035:154–60. 10.1016/j.aca.2018.06.032.10.1016/j.aca.2018.06.032 ↗
38. Khademi Z, Lavaee P, Ramezani M, Alibolandi M, Abnous K, Taghdisi SM. Co-delivery of doxorubicin and aptamer against Forkhead box M1 using chitosan-gold nanoparticles coated with nucleolin aptamer for synergistic treatment of cancer cells. Carbohydr Polym. 2020;248:116735. 10.1016/j.carbpol.2020.116735.10.1016/j.carbpol.2020.116735 ↗
39. Feng B, Xing Y, Lan J, Su Z, Wang F. Synthesis of MUC1 aptamer-stabilized gold nanoclusters for cell-specific imaging. Talanta. 2020;212:120796. 10.1016/j.talanta.2020.120796.10.1016/j.talanta.2020.120796 ↗
40. Vijayakumar S, Nasr SH, Davis JE, Wang E, Zuidema JM, Lu YS, et al. Anti-KIT DNA aptamer-conjugated porous silicon nanoparticles for the targeted detection of gastrointestinal stromal tumors. Nanoscale. 2022;14:17700–13. 10.1039/d2nr03905b.10.1039/D2NR03905B ↗
41. Alibolandi M, Hoseini F, Mohammadi M, Ramezani P, Einafshar E, Taghdisi SM, et al. Curcumin-entrapped MUC-1 aptamer targeted dendrimer-gold hybrid nanostructure as a theranostic system for colon adenocarcinoma. Int J Pharm. 2018;549:67–75. 10.1016/j.ijpharm.2018.07.052.10.1016/j.ijpharm.2018.07.052 ↗
42. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4:3689–96. 10.1021/nn901877h.10.1021/nn901877h ↗
43. Mohaghegh S, Tarighatnia A, Omidi Y, Barar J, Aghanejad A, Adibkia K. Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer. J Microencapsul. 2022;39:394–408. 10.1080/02652048.2022.2094487.10.1080/02652048.2022.2094487 ↗
44. Wang Z, Wu C, Liu J, Hu S, Yu J, Yin Q, et al. Aptamer-mediated hollow MnO2 for targeting the delivery of sorafenib. Drug Deliv. 2023;30:28–39. 10.1080/10717544.2022.2149897.10.1080/10717544.2022.2149897 ↗
45. Hasannia M, Lamei K, Abnous K, Taghdisi SM, Nekooei S, Nekooei N, et al. Targeted poly (L-glutamic acid)-based hybrid peptosomes co-loaded with doxorubicin and USPIONs as a theranostic platform for metastatic breast cancer. Nanomedicine. 2023;48:102645. 10.1016/j.nano.2022.102645.10.1016/j.nano.2022.102645 ↗
46. Zou Q, Zhang CJ, Yan YZ, Min ZJ, Li CS. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment. J Cell Biochem. 2019;120:18650–8. 10.1002/jcb.28950.10.1002/jcb.28950 ↗
47. Li J, You J, Wu C, Dai Y, Shi M, Dong L, et al. T1–T2 molecular magnetic resonance imaging of renal carcinoma cells based on nano-contrast agents, Int J Nanomed. 2018;13:4607–25. 10.2147/IJN.S168660.10.2147/IJN.S168660 ↗
48. Zhao M, Liu Z, Dong L, Zhou H, Yang S, Wu W, et al. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma. Int J Nanomed. 2018;13:4433–43. 10.2147/IJN.S168268.10.2147/IJN.S168268 ↗
49. Zhong L, Zou H, Huang Y, Gong W, He J, Tan J, et al. Magnetic endoglin aptamer nanoprobe for targeted diagnosis of solid tumor. J Biomed Nanotechnol. 2019;15:352–62. 10.1166/jbn.2019.2688.10.1166/jbn.2019.2688 ↗
50. Heo D, Ku M, Kim JH, Yang J, Suh JS. Aptamer-modified magnetic nanosensitizer for in vivo MR imaging of HER2-expressing cancer. Nanoscale Res Lett. 2018;13:288. 10.1186/s11671-018-2682-3.10.1186/s11671-018-2682-3 ↗
51. Zhong J, Ding J, Deng L, Xiang Y, Liu D, Zhang Y, et al. Selection of DNA aptamers recognizing EpCAM-positive prostate cancer by cell-SELEX for in vitro and in vivo MR imaging. Drug Des Dev Ther. 2021;15:3985–96. 10.2147/DDDT.S322854.10.2147/DDDT.S322854 ↗
52. Fang Y, Lin S, Yang F, Situ J, Lin S, Luo Y. Aptamer-conjugated multifunctional polymeric nanoparticles as cancer-targeted, MRI-ultrasensitive drug delivery systems for treatment of castration-resistant prostate cancer. Biomed Res Int. 2020;2020:9186583. 10.1155/2020/9186583.10.1155/2020/9186583 ↗
53. Zhao C, Song X, Jin W, Wu F, Zhang Q, Zhang M, et al. Image-guided cancer therapy using aptamer-functionalized cross-linked magnetic-responsive Fe3O4@carbon nanoparticles. Anal Chim Acta. 2019;1056:108–16. 10.1016/j.aca.2018.12.045.10.1016/j.aca.2018.12.045 ↗
54. Li F, Zeng Z, Hamilton D, Zu Y, Li Z. EpCAM-targeting aptamer radiotracer for tumor-specific PET imaging. Bioconjug Chem. 2021;32:1139–45. 10.1021/acs.bioconjchem.1c00188.10.1021/acs.bioconjchem.1c00188 ↗
55. Jiao Y, Xu P, Luan S, Wang X, Gao Y, Zhao C, et al. Molecular imaging and treatment of PSMA-positive prostate cancer with 99mTc radiolabeled aptamer-siRNA chimeras. Nucl Med Biol. 2022;104–105:28–37. 10.1016/j.nucmedbio.2021.11.003.10.1016/j.nucmedbio.2021.11.003 ↗
56. Kim J, Yu AM, Kubelick KP, Emelianov SY. Gold nanoparticles conjugated with DNA aptamer for photoacoustic detection of human matrix metalloproteinase-9. Photoacoustics. 2022;25:100307. 10.1016/j.pacs.2021.100307.10.1016/j.pacs.2021.100307 ↗
57. He Y, Wang M, Fu M, Yuan X, Luo Y, Qiao B, et al. Iron(II) phthalocyanine loaded and AS1411 aptamer targeting nanoparticles: A nanocomplex for dual modal imaging and photothermal therapy of breast cancer. Int J Nanomed. 2020;15:5927–49. 10.2147/IJN.S254108.10.2147/IJN.S254108 ↗
58. You Y, Cheng W, Chen H. Application of ultrasound molecular imaging based on compressed sensing reconstruction algorithm to phase change drug-loaded PLGA nanoparticles targeting breast cancer MCF-7 Cells. Pak J Med Sci. 2021;37:1610–4. 10.12669/pjms.37.6-WIT.4852.10.12669/pjms.37.6-WIT.4852 ↗
59. Kang Z, Yang M, Feng X, Liao H, Zhang Z, Du Y. Multifunctional theranostic nanoparticles for enhanced tumor targeted imaging and synergistic FUS/chemotherapy on murine 4T1 breast cancer cell. Int J Nanomed. 2022;17:2165–87. 10.2147/IJN.S360161.10.2147/IJN.S360161 ↗
60. Zhu L, Wang L, Liu Y, Xu D, Fang K, Guo Y. CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors. Int J Nanomed. 2018;13:6481–95. 10.2147/IJN.S176287.10.2147/IJN.S176287 ↗
61. Fang K, Wang L, Huang H, Lan M, Shen D, Dong S, et al. Construction of nucleolin-targeted lipid nanobubbles and contrast-enhanced ultrasound molecular imaging in triple-negative breast cancer. Pharm Res. 2020;37:145. 10.1007/s11095-020-02873-1.10.1007/s11095-020-02873-1 ↗
62. Fang K, Wang L, Huang H, Dong S, Guo Y. Therapeutic efficacy and cardioprotection of nucleolin-targeted doxorubicin-loaded ultrasound nanobubbles in treating triple-negative breast cancer. Nanotechnology. 2021;32:245102. 10.1088/1361-6528/abed03.10.1088/1361-6528/abed03 ↗
63. Cai P, Su D, Yang W, He Z, Zhang C, Liu H, et al. Inherently PET/CT dual modality imaging lipid nanocapsules for early detection of orthotopic lung tumors. ACS Appl Bio Mater. 2020;3:611–21. 10.1021/acsabm.9b00993.10.1021/acsabm.9b00993 ↗
64. Huang X, Zhong J, Ren J, Wen D, Zhao W, Huan Y. A DNA aptamer recognizing MMP14 for in vivo and in vitro imaging identified by cell-SELEX. Oncol Lett. 2019;18:265–74. 10.3892/ol.2019.10282.10.3892/ol.2019.10282 ↗
65. Zhang W, Zhou R, Yang Y, Peng S, Xiao D, Kong T, et al. Aptamer-mediated synthesis of multifunctional nano-hydroxyapatite for active tumour bioimaging and treatment. Cell Prolif. 2021;54:e13105. 10.1111/cpr.13105.10.1111/cpr.13105 ↗
66. Jiang Y, Zhao W, Zhou H, Zhang Q, Zhang S. ATP-triggered intracellular in situ aggregation of a gold-nanoparticle-equipped triple-helix molecular switch for fluorescence imaging and photothermal tumor therapy. Langmuir. 2022;38:3755–64. 10.1021/acs.langmuir.1c03331.10.1021/acs.langmuir.1c03331 ↗
67. Wang L, Niu M, Zheng C, Zhao H, Niu X, Li L, et al. A core-shell nanoplatform for synergistic enhanced sonodynamic therapy of hypoxic tumor via cascaded strategy. Adv Healthc Mater. 2018;7:e1800819. 10.1002/adhm.201800819.10.1002/adhm.201800819 ↗
68. Chinnappan R, Al FA, Abdel RA, Abu-Salah KM, Mouffouk F, Zourob M. Anti-VCAM-1 and Anti-IL4Rα aptamer-conjugated super paramagnetic iron oxide nanoparticles for enhanced breast cancer diagnosis and therapy. Molecules. 2020;25:3437. 10.3390/molecules25153437.10.3390/molecules25153437 ↗
69. Zhang M, Wang W, Wu F, Graveran K, Zhang J, Wu C. Black phosphorus quantum dots gated, carbon-coated Fe3O4 nanocapsules (BPQDs@ss-Fe3 O4 @C) with low premature release could enable imaging-guided cancer combination therapy. Chem Eur J. 2018;24:12890–901. 10.1002/chem.201801085.10.1002/chem.201801085 ↗
70. Akbarzadeh M, Babaei M, Abnous K, Taghdisi SM, Peivandi MT, Ramezani M, et al. Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system. Int J Pharm. 2019;570:118645. 10.1016/j.ijpharm.2019.118645.10.1016/j.ijpharm.2019.118645 ↗
71. Zheng S, Zhang M, Bai H, He M, Dong L, Cai L, et al. Preparation of AS1411 aptamer modified Mn-MoS2 QDs for targeted MR imaging and fluorescence labelling of renal cell carcinoma. Int J Nanomed. 2019;14:9513–24. 10.2147/IJN.S215883.10.2147/IJN.S215883 ↗
72. Wu M, Zhao H, Guo L, Wang Y, Song J, Zhao X, et al. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer. Drug Deliv. 2018;25:226–40. 10.1080/10717544.2017.1422300.10.1080/10717544.2017.1422300 ↗
73. Wu M, Wang Y, Wang Y, Zhang M, Luo Y, Tang J, et al. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer. Int J Nanomed. 2017;12:5313–30. 10.2147/IJN.S136032.10.2147/IJN.S136032 ↗
74. Zhang W, Ding X, Cheng H, Yin C, Yan J, Mou Z, et al. Dual-targeted gold nanoprism for recognition of early apoptosis, dual-model imaging, and precise cancer photothermal therapy. Theranostics. 2019;9:5610–25. 10.7150/thno.34755.10.7150/thno.34755 ↗
75. Dai Y, Zhao H, He K, Du W, Kong Y, Wang Z, et al. NIR-II excitation phototheranostic nanomedicine for fluorescence/photoacoustic tumor imaging and targeted photothermal-photonic thermodynamic therapy. Small. 2021;17:e2102527. 10.1002/smll.202102527.10.1002/smll.202102527 ↗
76. Chang W, Wang J, Zhang J, Ling Q, Li Y, Wang J. High performance gold nanorods@DNA self-assembled drug-loading system for cancer thermo-chemotherapy in the second near-infrared optical window. Pharmaceutics. 2022;14:1110. 10.3390/pharmaceutics14051110.10.3390/pharmaceutics14051110 ↗
77. Najdian A, Amanlou M, Beiki D, Bitarafan-Rajabi A, Mirzaei M, Shafiee AM. Amino-modified-silica-coated gadolinium-copper nanoclusters, conjugated to AS1411 aptamer and radiolabeled with technetium-99 m as a novel multimodal imaging agent. Bioorg Chem. 2022;125:105827. 10.1016/j.bioorg.2022.105827.10.1016/j.bioorg.2022.105827 ↗
78. Sivakumar B, Aswathy RG, Romero-Aburto R, Mitcham T, Mitchel KA, Nagaoka Y, et al. Highly versatile SPION encapsulated PLGA nanoparticles as photothermal ablators of cancer cells and as multimodal imaging agents. Biomater Sci. 2017;5:432–43. 10.1039/c6bm00621c.10.1039/C6BM00621C ↗
79. Fletcher NL, Houston ZH, Simpson JD, Veedu RN, Thurecht KJ. Designed multifunctional polymeric nanomedicines: Long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials. Chem Commun. 2018;54:11538–41. 10.1039/c8cc05831h.10.1039/C8CC05831H ↗
80. Xu M, Xue B, Wang Y, Wang D, Gao D, Yang S, et al. Temperature-feedback nanoplatform for NIR-II penta-modal imaging-guided synergistic photothermal therapy and CAR-NK immunotherapy of lung cancer. Small. 2021;17:e2101397. 10.1002/smll.202101397.10.1002/smll.202101397 ↗
81. Liu M, Wang L, Lo Y, Shiu SC, Kinghorn AB, Tanner JA. Aptamer-enabled nanomaterials for therapeutics, drug targeting and imaging. Cells. 2022;11:159. 10.3390/cells11010159.10.3390/cells11010159 ↗
82. Xu Y, Luo C, Wang J, Chen L, Chen J, Chen T, et al. Application of nanotechnology in the diagnosis and treatment of bladder cancer. J Nanobiotechnol. 2021;19:393. 10.1186/s12951-021-01104-y.10.1186/s12951-021-01104-y ↗
83. Ma W, Zhan Y, Zhang Y, Mao C, Xie X, Lin Y. The biological applications of DNA nanomaterials: current challenges and future directions. Signal Transduct Target Ther. 2021;6:351. 10.1038/s41392-021-00727-9.10.1038/s41392-021-00727-9 ↗
84. Tian R, Shang Y, Wang Y, Jiang Q, Ding B. DNA nanomaterials-based platforms for cancer immunotherapy. Small Methods. 2023;7:e2201518. 10.1002/smtd.202201518.10.1002/smtd.202201518 ↗
85. Zhan Y, Ma W, Zhang Y, Mao C, Shao X, Xie X, et al. Diversity of DNA nanostructures and applications in oncotherapy. Biotechnol J. 2020;15:e1900094. 10.1002/biot.201900094.10.1002/biot.201900094 ↗
86. Meng HM, Liu H, Kuai H, Peng R, Mo L, Zhang XB. Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy. Chem Soc Rev. 2016;45:2583–602. 10.1039/c5cs00645g.10.1039/C5CS00645G ↗
87. Charbgoo F, Alibolandi M, Taghdisi SM, Abnous K, Soltani F, Ramezani M. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide. Nanomedicine. 2018;14:685–97. 10.1016/j.nano.2017.12.010.10.1016/j.nano.2017.12.010 ↗
88. Li Z, Liu M, Ke L, Wang LJ, Wu C, Li C, et al. Flexible polymeric nanosized micelles for ophthalmic drug delivery: research progress in the last three years. Nanoscale Adv. 2021;3:5240–54. 10.1039/d1na00596k.10.1039/D1NA00596K ↗
89. Kotta S, Aldawsari HM, Badr-Eldin SM, Nair AB, Yt K. Progress in polymeric micelles for drug delivery applications. Pharmaceutics. 2022;14:1636. 10.3390/pharmaceutics14081636.10.3390/pharmaceutics14081636 ↗
90. Miyamoto D, Tang Z, Takarada T, Maeda M. Turbidimetric detection of ATP using polymeric micelles and DNA aptamers. Chem Commun. 2007;7:4743–5. 10.1039/b709775a.10.1039/b709775a ↗
91. Tian J, Ding L, Ju H, Yang Y, Li X, Shen Z, et al. A multifunctional nanomicelle for real-time targeted imaging and precise near-infrared cancer therapy. Angew Chem Int Ed. 2014;53:9544–9. 10.1002/anie.201405490.10.1002/anie.201405490 ↗
92. Wei J, Xue W, Yu X, Qiu X, Liu Z. pH sensitive phosphorylated chitosan hydrogel as vaccine delivery system for intramuscular immunization. J Biomater Appl. 2017;31:1358–69. 10.1177/0885328217704139.10.1177/0885328217704139 ↗
93. Gasztych M, Komsa K, Musia W. Influence of hydrophilic co-monomer on the drug release from hydrogels with thermosensitive N-(isopropyl)acrylamide derivatives. J Nanosci Nanotechnol. 2019;19:2514–21. 10.1166/jnn.2019.15848.10.1166/jnn.2019.15848 ↗
94. Lai J, Li S, Shi X, Coyne J, Zhao N, Dong F, et al. Displacement and hybridization reactions in aptamer-functionalized hydrogels for biomimetic protein release and signal transduction. Chem Sci. 2017;8:7306–11. 10.1039/c7sc03023a.10.1039/C7SC03023A ↗
95. Rocha CV, Gonçalves V, Da SM, Bañobre-López M, Gallo J. PLGA-based composites for various biomedical applications. Int J Mol Sci. 2022;23:2034. 10.3390/ijms23042034.10.3390/ijms23042034 ↗
96. Vandghanooni S, Eskandani M, Barar J, Omidi Y. AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. Nanomedicine. 2018;13:2729–58. 10.2217/nnm-2018-0205.10.2217/nnm-2018-0205 ↗
97. Askarian S, Abnous K, Taghavi S, Oskuee RK, Ramezani M. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles. Colloid Surf B Biointerfaces. 2015;136:355–64. 10.1016/j.colsurfb.2015.09.023.10.1016/j.colsurfb.2015.09.023 ↗
98. Sanati S, Taghavi S, Abnous K, Taghdisi SM, Babaei M, Ramezani M, et al. Fabrication of anionic dextran-coated micelles for aptamer targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinoma. Gene Ther. 2022;29:55–68. 10.1038/s41434-021-00234-0.10.1038/s41434-021-00234-0 ↗
99. Moosavian SA, Abnous K, Akhtari J, Arabi L, Gholamzade DA, Jafari M. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artif Cell Nanomed Biotechnol. 2018;46:2054–65. 10.1080/21691401.2017.1408120.10.1080/21691401.2017.1408120 ↗
100. Mosafer J, Abnous K, Tafaghodi M, Mokhtarzadeh A, Ramezani M. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy. Eur J Pharm Biopharm. 2017;113:60–74. 10.1016/j.ejpb.2016.12.009.10.1016/j.ejpb.2016.12.009 ↗